NZ706723A - Novel process for making compounds for use in the treatment of cancer - Google Patents
Novel process for making compounds for use in the treatment of cancerInfo
- Publication number
- NZ706723A NZ706723A NZ706723A NZ70672313A NZ706723A NZ 706723 A NZ706723 A NZ 706723A NZ 706723 A NZ706723 A NZ 706723A NZ 70672313 A NZ70672313 A NZ 70672313A NZ 706723 A NZ706723 A NZ 706723A
- Authority
- NZ
- New Zealand
- Prior art keywords
- cancer
- treatment
- novel process
- making compounds
- making
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ706723A true NZ706723A (en) | 2018-07-27 |
Family
ID=49474740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ706723A NZ706723A (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (enExample) |
| EP (1) | EP2909188B1 (enExample) |
| JP (2) | JP6300042B2 (enExample) |
| KR (1) | KR102204520B1 (enExample) |
| CN (2) | CN108948043B (enExample) |
| AU (1) | AU2013328929B2 (enExample) |
| BR (1) | BR112015008113B1 (enExample) |
| CA (1) | CA2889466C (enExample) |
| CL (1) | CL2015000926A1 (enExample) |
| CR (2) | CR20200237A (enExample) |
| EA (1) | EA030613B1 (enExample) |
| ES (1) | ES2671502T3 (enExample) |
| GE (1) | GEP201706690B (enExample) |
| HK (1) | HK1213567A1 (enExample) |
| HR (1) | HRP20180670T1 (enExample) |
| IL (1) | IL238116B (enExample) |
| IN (1) | IN2015DN03928A (enExample) |
| MA (1) | MA38085B1 (enExample) |
| MX (2) | MX372708B (enExample) |
| MY (1) | MY186549A (enExample) |
| NZ (1) | NZ706723A (enExample) |
| PE (3) | PE20191818A1 (enExample) |
| PH (1) | PH12015500785A1 (enExample) |
| PL (1) | PL2909188T3 (enExample) |
| SA (1) | SA515360271B1 (enExample) |
| SG (1) | SG11201502795VA (enExample) |
| SI (1) | SI2909188T1 (enExample) |
| TR (1) | TR201807861T4 (enExample) |
| UA (1) | UA115455C2 (enExample) |
| WO (1) | WO2014059422A1 (enExample) |
| ZA (1) | ZA201502349B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| TWI804919B (zh) | 2015-06-30 | 2023-06-11 | 美商建南德克公司 | 含藥物之立即釋放錠劑及形成該錠劑的方法 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| CN105330643B (zh) | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| CN109689102A (zh) | 2016-08-12 | 2019-04-26 | 基因泰克公司 | Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法 |
| WO2018064299A1 (en) | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| CN117940130A (zh) | 2021-03-09 | 2024-04-26 | 基因泰克公司 | 用于脑癌治疗的贝伐拉非尼 |
| CN117561062A (zh) | 2021-04-06 | 2024-02-13 | 基因泰克公司 | 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| AU685933B2 (en) | 1994-04-01 | 1998-01-29 | Shionogi & Co., Ltd. | Oxime derivative and bactericide containing the same as active ingredient |
| WO1997012613A1 (en) | 1995-10-05 | 1997-04-10 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| AU5610398A (en) | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| ES2229515T3 (es) | 1997-07-01 | 2005-04-16 | Warner-Lambert Company Llc | Derivados 4-bromo o 4-yodo del acido fenilamino benzhidroxamico y su uso como inhibidores de la mek. |
| ATE344791T1 (de) * | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| AU2180500A (en) | 1998-12-15 | 2000-07-03 | Warner-Lambert Company | Use of a mek inhibitor for preventing transplant rejection |
| JP2002532415A (ja) | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
| KR20010099877A (ko) | 1998-12-22 | 2001-11-09 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 배합물 화학요법 |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| CA2350234A1 (en) | 1999-01-07 | 2000-07-13 | Alexander James Bridges | Treatment of asthma with mek inhibitors |
| JP2002534381A (ja) | 1999-01-07 | 2002-10-15 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤を用いた抗ウィルス法 |
| ID30439A (id) | 1999-01-13 | 2001-12-06 | Warner Lambert Co | Benzoheterosiklus dan penggunaannya sebagai penghambat mek |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| JP2002534515A (ja) | 1999-01-13 | 2002-10-15 | ワーナー−ランバート・カンパニー | １−複素環置換されたジアリールアミン |
| HUP0202381A3 (en) | 1999-07-16 | 2004-12-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| ATE250932T1 (de) | 1999-07-16 | 2003-10-15 | Warner Lambert Co | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
| IL147150A0 (en) | 1999-07-16 | 2002-08-14 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| HUP0202623A3 (en) | 1999-07-16 | 2003-03-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
| CZ2002961A3 (cs) | 1999-09-17 | 2002-08-14 | Millennium Pharmaceuticals, Inc. | Benzamidy a příbuzné sloučeniny pro inhibici faktoru Xa |
| JP2003527379A (ja) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類 |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| AU7349801A (en) | 2000-07-19 | 2002-01-30 | Warner Lambert Co | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids |
| AP2001002249A0 (en) * | 2000-08-25 | 2001-09-30 | Warner Lambert Co | Process for making N-ARYL-ANTHRANILIC acids and their derivatives. |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| BR0213696A (pt) | 2001-10-31 | 2004-10-26 | Pfizer Prod Inc | Agonistas do receptor de acetilcolina nicotìnicos no tratamento da sìndrome de pernas inquietas |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| BR0307060A (pt) | 2002-01-23 | 2004-10-26 | Warner Lambert Co | ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| SG2013013339A (en) | 2002-03-13 | 2014-12-30 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| WO2003077855A2 (en) | 2002-03-13 | 2003-09-25 | Array Biopharma, Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
| CA2488567A1 (en) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| US20060094674A1 (en) | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| KR101099281B1 (ko) | 2003-03-03 | 2011-12-26 | 어레이 바이오파마 인크. | ｐ38 억제제 및 그의 사용 방법 |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| AU2004249495A1 (en) | 2003-06-20 | 2004-12-29 | Ucb Pharma S.A. | Thienopyridone derivatives as kinase inhibitors |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| CA2532067C (en) | 2003-07-24 | 2010-12-21 | Stephen Douglas Barrett | N-methyle-substituted benzamidazoles |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| JP4931419B2 (ja) | 2003-09-19 | 2012-05-16 | 中外製薬株式会社 | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのｍｅｋ阻害剤としての使用 |
| KR101190912B1 (ko) | 2003-11-19 | 2012-10-12 | 어레이 바이오파마 인크. | Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법 |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CA2547804A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivatives |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| ES2444866T3 (es) * | 2004-10-20 | 2014-02-27 | Merck Serono Sa | Derivados de 3-arilamino piridina |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| NZ567140A (en) * | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetidines as MEK inhibitors for the treatment of proliferative diseases |
| CA2658725A1 (en) | 2006-08-16 | 2008-02-21 | Exelixis, Inc. | Using pi3k and mek modulators in treatments of cancer |
| WO2008076415A1 (en) * | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| SI2909188T1 (en) | 2012-10-12 | 2018-07-31 | Exelixis, Inc. | A novel process for the manufacture of compounds for use in the treatment of cancer |
| CN105992755B (zh) | 2014-02-07 | 2018-07-13 | 住友化学株式会社 | (r)-1,1,3-三甲基-4-氨基茚满的制造方法 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-08 PH PH12015500785A patent/PH12015500785A1/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020005533A (es) | Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek. | |
| NZ705705A (en) | Ret inhibitor | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| PH12015502284B1 (en) | Protein kinase inhibitors | |
| MA40076A (fr) | Inhibiteurs de syk | |
| PH12021552233A1 (en) | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kd RELATED DISORDERS | |
| NZ715747A (en) | Syk inhibitors | |
| MX2015009209A (es) | Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos. | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| NZ736970A (en) | Process methods for phosphatidylinositol 3-kinase inhibitors | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| MX351863B (es) | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. | |
| PH12015500867A1 (en) | Treatment of prostate cancer with tor kinase inhibitors | |
| PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| MX2013010050A (es) | Inhibidor de proteasoma delanzomib para uso en el tratamiento de lupus. | |
| IN2014DN00123A (enExample) | ||
| IN2014DN10658A (enExample) | ||
| IN2014KN01772A (enExample) | ||
| SG10201706035QA (en) | Use of phenoxypropylamine compounds to treat depression | |
| TN2014000418A1 (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
| GEP20176633B (en) | Use of pidotimod to treat psoriasis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ASS | Change of ownership |
Owner name: EXELIXIS, INC., US Effective date: 20150528 Owner name: GENENTECH, INC., US Effective date: 20150528 |
|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2020 BY CPA GLOBAL Effective date: 20190912 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2021 BY CPA GLOBAL Effective date: 20200917 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2022 BY CPA GLOBAL Effective date: 20210916 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2023 BY CPA GLOBAL Effective date: 20220915 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2024 BY CPA GLOBAL Effective date: 20230914 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2025 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20240912 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 OCT 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS Effective date: 20250911 |